pI: 8.0282 |
Length (AA): 1040 |
MW (Da): 118285 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 2
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Ortholog group members (OG5_139129)
Species | Accession | Gene Product |
---|---|---|
Brugia malayi | Bm1_02170 | hypothetical protein |
Leishmania braziliensis | LbrM.09.0630 | phospholipid transporting ATPase-like protein, putative |
Leishmania donovani | LdBPK_090940.1 | phospholipid transporting ATPase-like protein, putative |
Leishmania infantum | LinJ.09.0940 | phospholipid transporting ATPase-like protein, putative |
Leishmania major | LmjF.09.0890 | phospholipid transporting ATPase-like protein, putative |
Leishmania mexicana | LmxM.09.0890 | phospholipid transporting ATPase-like protein, putative |
Neospora caninum | NCLIV_059860 | ATPase 2, putative |
Trypanosoma brucei gambiense | Tbg972.11.14460 | phospholipid-transporting ATPase, putative |
Trypanosoma brucei | Tb927.11.13000 | phospholipid-transporting ATPase, putative |
Trypanosoma cruzi | TcCLB.505171.10 | phospholipid transporting ATPase-like protein, putative |
Toxoplasma gondii | TGME49_216380 | phospholipid-translocating P-type ATPase, flippase subfamily protein |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb11.52.0018 | Trypanosoma brucei | significant gain of fitness in bloodstream forms (3 days) | alsford |
Tb11.52.0018 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb11.52.0018 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb11.52.0018 | Trypanosoma brucei | significant gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
TGME49_216380 | Toxoplasma gondii | Essentiality uncertain | sidik |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.